NASDAQ Endocrinology Market News

Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term

Lisbon, Portugal, 12 September 2017 ­­­- Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ...

Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term

Lisbon, Portugal, 12 September 2017 ­­­- Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ...

[sam_pro id=0_12 codes="true"]